Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

10.0K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
10.0K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

5.5K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K
Cancer Therapies02:49

Cancer Therapies

9.8K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.8K
Tumor Immunotherapy01:27

Tumor Immunotherapy

1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Short-Term Exposure to a 50 Hz Extremely Low-Frequency Electromagnetic Field (ELF-EMF) Leads to ROS-Mediated DNA Damage in Gynecological and Urological Cancer Cells <i>In Vitro</i>.

International journal of molecular sciences·2026
Same author

Soma-derived 30-nt small RNAs are coupled with chromosome breakage and precisely target nontransposon DNA against elimination in <i>Euplotes vannus</i>.

Science advances·2025
Same author

Visible-Light-Induced Bond Homolysis in Titanacyclopentadienes for the Catalytic Cyclodimerization of Internal Alkynes.

Journal of the American Chemical Society·2025
Same author

The In Vitro Enhancement of Retinal Cell Viability via m<sup>6</sup>A and m<sup>5</sup>C RNA Methylation-Mediated Changes in the Levels of Heme Oxygenase (HO-1) and DNA Damage Repair Molecules Using a 50 Hz Sinusoidal Electromagnetic Field (EMF).

International journal of molecular sciences·2025
Same author

Association of the benzoxazinoid pathway with boron homeostasis in maize.

Plant physiology·2024
Same author

Controllable 1,4-Palladium Aryl to Aryl Migration in Fused Systems─Application to the Synthesis of Azaborole Multihelicenes.

Journal of the American Chemical Society·2024

Related Experiment Video

Updated: Jan 14, 2026

Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells
09:37

Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells

Published on: August 25, 2021

2.1K

HuR-Targeted Small-Molecule Inhibitors─Beneficial Impact in Cancer Therapy.

Iwona Rzeszutek1, Agnieszka Nowak-Król2

  • 1Interdisciplinary Centre for Preclinical and Clinical Research, Faculty of Biotechnology, Collegium Medicum, University of Rzeszow, Werynia 2a, 36-100 Kolbuszowa, Poland.

Journal of Medicinal Chemistry
|October 17, 2025
PubMed
Summary

Small-molecule inhibitors targeting HuR (human antigen R) are revolutionizing cancer therapy. These drugs harness HuR

More Related Videos

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer
10:46

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer

Published on: September 13, 2022

4.3K
Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

1.1K

Related Experiment Videos

Last Updated: Jan 14, 2026

Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells
09:37

Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells

Published on: August 25, 2021

2.1K
A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer
10:46

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer

Published on: September 13, 2022

4.3K
Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

1.1K

Area of Science:

  • Oncology
  • Molecular Biology
  • Drug Discovery

Background:

  • Small-molecule inhibitors (SMIs) represent a significant therapeutic advancement in cancer treatment.
  • The RNA-binding protein HuR (human antigen R) plays a crucial role in cancer progression.
  • HuR regulates gene expression post-transcriptionally, influencing cellular transcript fate.

Purpose of the Study:

  • To summarize the role of HuR in the progression of various cancers.
  • To review the effects of existing HuR-targeted small-molecule inhibitors (SMIs) across numerous cancer types.
  • To highlight future perspectives in the development of HuR-targeted cancer therapies.

Main Methods:

  • Literature review of studies investigating HuR's function in cancer.
  • Compilation and analysis of data on currently available HuR-targeted SMIs.
  • Synthesis of information on the efficacy and application of these inhibitors in preclinical and clinical settings.

Main Results:

  • HuR is implicated in multiple stages of cancer development and progression.
  • Several SMIs targeting HuR have demonstrated potential in preclinical cancer models.
  • Targeted therapy using HuR-SMIs shows promise for accelerating cancer treatment efficacy.

Conclusions:

  • HuR is a validated therapeutic target for small-molecule inhibitor development in oncology.
  • HuR-targeted SMIs offer a promising avenue for novel cancer treatment strategies.
  • Further research is warranted to optimize HuR-targeted therapies and expand their clinical application.